Terms: = Endocrine gland cancer AND ATR, Q13535, 545, ENSG00000175054, MEC1, SCKL, SCKL1, FRP1 AND Prognosis
44 results:
1. Undifferentiated Carcinoma with Osteoclast-like Giant Cells of the Pancreas: Molecular Genetic Analysis of 13 Cases.
Hrudka J; Kalinová M; Ciprová V; Moravcová J; Dvořák R; Matěj R
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542259
[TBL] [Abstract] [Full Text] [Related]
2. Selectively targeting BCL6 using a small molecule inhibitor is a potential therapeutic strategy for ovarian cancer.
Wu M; Xie J; Xing Y; Zhang L; Chen H; Tang B; Zhou M; Lv S; Huang D; Jian S; Zhou C; Liu M; Guo W; Chen Y; Yi Z
Int J Biol Sci; 2024; 20(2):486-501. PubMed ID: 38169532
[TBL] [Abstract] [Full Text] [Related]
3. Preclinical Synergistic Combination Therapy of Lurbinectedin with Irinotecan and 5-Fluorouracil in Pancreatic cancer.
Tummala T; Sevilla Uruchurtu AS; Cruz A; Huntington KE; George A; Liguori NR; Zhang L; Zhou L; Abbas AE; Azzoli CG; El-Deiry WS
Curr Oncol; 2023 Oct; 30(11):9611-9626. PubMed ID: 37999116
[TBL] [Abstract] [Full Text] [Related]
4. Outcomes of lung oligometastasis in pancreatic cancer.
Takeda T; Sasaki T; Ichinose J; Inoue Y; Okamoto T; Mie T; Furukawa T; Kasuga A; Oba A; Matsuura Y; Nakao M; Ozaka M; Mun M; Takahashi Y; Sasahira N
Jpn J Clin Oncol; 2023 Dec; 53(12):1144-1152. PubMed ID: 37609670
[TBL] [Abstract] [Full Text] [Related]
5. Postoperative hyperprogression disease of pancreatic ductal adenocarcinoma after curative resection: a retrospective cohort study.
Zou S; Wang X; Chen H; Lin J; Wen C; Zhan Q; Chen H; Lu X; Deng X; Shen B
BMC Cancer; 2022 Jun; 22(1):649. PubMed ID: 35698045
[TBL] [Abstract] [Full Text] [Related]
6. Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8
Heinze K; Nazeran TM; Lee S; Krämer P; Cairns ES; Chiu DS; Leung SC; Kang EY; Meagher NS; Kennedy CJ; Boros J; Kommoss F; Vollert HW; Heitz F; du Bois A; Harter P; Grube M; Kraemer B; Staebler A; Kommoss FK; Heublein S; Sinn HP; Singh N; Laslavic A; Elishaev E; Olawaiye A; Moysich K; Modugno F; Sharma R; Brand AH; Harnett PR; DeFazio A; Fortner RT; Lubinski J; Lener M; Tołoczko-Grabarek A; Cybulski C; Gronwald H; Gronwald J; Coulson P; El-Bahrawy MA; Jones ME; Schoemaker MJ; Swerdlow AJ; Gorringe KL; Campbell I; Cook L; Gayther SA; Carney ME; Shvetsov YB; Hernandez BY; Wilkens LR; Goodman MT; Mateoiu C; Linder A; Sundfeldt K; Kelemen LE; Gentry-Maharaj A; Widschwendter M; Menon U; Bolton KL; Alsop J; Shah M; Jimenez-Linan M; Pharoah PD; Brenton JD; Cushing-Haugen KL; Harris HR; Doherty JA; Gilks B; Ghatage P; Huntsman DG; Nelson GS; Tinker AV; Lee CH; Goode EL; Nelson BH; Ramus SJ; Kommoss S; Talhouk A; Köbel M; Anglesio MS
J Pathol; 2022 Apr; 256(4):388-401. PubMed ID: 34897700
[TBL] [Abstract] [Full Text] [Related]
7. Genomic mutation features identify distinct BRCA-associated mutation characteristics in endometrioid carcinoma and endometrioid ovarian carcinoma.
Cao C; Yu R; Gong W; Liu D; Zhang X; Fang Y; Xia Y; Zhang W; Gao Q
Aging (Albany NY); 2021 Nov; 13(22):24686-24709. PubMed ID: 34837690
[TBL] [Abstract] [Full Text] [Related]
8. Pre-operative radiomics model for prognostication in resectable pancreatic adenocarcinoma with external validation.
Healy GM; Salinas-Miranda E; Jain R; Dong X; Deniffel D; Borgida A; Hosni A; Ryan DT; Njeze N; McGuire A; Conlon KC; Dodd JD; Ryan ER; Grant RC; Gallinger S; Haider MA
Eur Radiol; 2022 Apr; 32(4):2492-2505. PubMed ID: 34757450
[TBL] [Abstract] [Full Text] [Related]
9. A 6 transcription factors-associated nomogram predicts the recurrence-free survival of thyroid papillary carcinoma.
Wang T; Tian K; Ji X; Song F
Medicine (Baltimore); 2021 Oct; 100(40):e27308. PubMed ID: 34622829
[TBL] [Abstract] [Full Text] [Related]
10. Inhibitor library screening identifies ispinesib as a new potential chemotherapeutic agent for pancreatic cancers.
Murase Y; Ono H; Ogawa K; Yoshioka R; Ishikawa Y; Ueda H; Akahoshi K; Ban D; Kudo A; Tanaka S; Tanabe M
Cancer Sci; 2021 Nov; 112(11):4641-4654. PubMed ID: 34510663
[TBL] [Abstract] [Full Text] [Related]
11. Co-regulation and function of
Barger CJ; Chee L; Albahrani M; Munoz-Trujillo C; Boghean L; Branick C; Odunsi K; Drapkin R; Zou L; Karpf AR
Elife; 2021 Apr; 10():. PubMed ID: 33890574
[TBL] [Abstract] [Full Text] [Related]
12. MicroRNA-545 suppresses progression of ovarian cancer through mediating PLK1 expression by a direct binding and an indirect regulation involving KDM4B-mediated demethylation.
Zhang H; Zhang K; Xu Z; Chen Z; Wang Q; Wang C; Cui J
BMC Cancer; 2021 Feb; 21(1):163. PubMed ID: 33588776
[TBL] [Abstract] [Full Text] [Related]
13. CD147 promotes DNA damage response and gemcitabine resistance via targeting ATM/atr/p53 and affects prognosis in pancreatic cancer.
Zhou Y; Zheng M; Liu Z; Yang H; Zhu P; Jiang JL; Tang J; Chen ZN
Biochem Biophys Res Commun; 2020 Jul; 528(1):62-70. PubMed ID: 32456796
[TBL] [Abstract] [Full Text] [Related]
14. Participation of the atr/CHK1 pathway in replicative stress targeted therapy of high-grade ovarian cancer.
Gralewska P; Gajek A; Marczak A; Rogalska A
J Hematol Oncol; 2020 Apr; 13(1):39. PubMed ID: 32316968
[TBL] [Abstract] [Full Text] [Related]
15. Targeting Ku86 enhances X-ray-induced radiotherapy sensitivity in serous ovarian cancer cells.
Ma Q; Kai J; Liu Y; Tong Y; Xie S; Zheng H; Wang Y; Guo L; Lu R
Int J Biochem Cell Biol; 2020 Apr; 121():105705. PubMed ID: 32027982
[TBL] [Abstract] [Full Text] [Related]
16. atr-FTIR spectroscopy and CDKN1C gene expression in the prediction of lymph nodes metastases in papillary thyroid carcinoma.
da Silva RM; Pupin B; Bhattacharjee TT; Vamondes Kulcsar MA; Uno M; Chammas R; de Azevedo Canevari R
Spectrochim Acta A Mol Biomol Spectrosc; 2020 Mar; 228():117693. PubMed ID: 31708464
[TBL] [Abstract] [Full Text] [Related]
17. Targeting the High-Mobility Group Box 3 Protein Sensitizes Chemoresistant Ovarian cancer Cells to Cisplatin.
Mukherjee A; Huynh V; Gaines K; Reh WA; Vasquez KM
Cancer Res; 2019 Jul; 79(13):3185-3191. PubMed ID: 31061066
[TBL] [Abstract] [Full Text] [Related]
18. Factors Associated With the Improved Survival of Head and Neck Neuroblastomas Compared to Other Body Sites.
Kaufmann MR; Camilon PR; Janz TA; Levi JR
Ann Otol Rhinol Laryngol; 2019 Mar; 128(3):241-248. PubMed ID: 30565471
[TBL] [Abstract] [Full Text] [Related]
19. Targeting Defects in the Cellular DNA Damage Response for the Treatment of Pancreatic Ductal Adenocarcinoma.
Schmitt A; Feldmann G; Zander T; Reinhardt HC
Oncol Res Treat; 2018; 41(10):619-625. PubMed ID: 30286473
[TBL] [Abstract] [Full Text] [Related]
20. DUOXA1-mediated ROS production promotes cisplatin resistance by activating atr-Chk1 pathway in ovarian cancer.
Meng Y; Chen CW; Yung MMH; Sun W; Sun J; Li Z; Li J; Li Z; Zhou W; Liu SS; Cheung ANY; Ngan HYS; Braisted JC; Kai Y; Peng W; Tzatsos A; Li Y; Dai Z; Zheng W; Chan DW; Zhu W
Cancer Lett; 2018 Aug; 428():104-116. PubMed ID: 29704517
[TBL] [Abstract] [Full Text] [Related]
[Next]
